{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-108324","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.036661+00:00","generated_at":"2026-05-15T12:16:18.827373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028","bullets":["Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).","Cash, equivalents, investments, and receivables $109.4M as of Dec 31, 2025; runway into 2028.","Phase 2 monotherapy trial of FG-3246 in mCRPC enrolling; interim analysis expected 2H 2026.","Phase 3 protocol for roxadustat in LR-MDS anemia submitted to FDA; start targeted 2H 2026.","Combo trial of FG-3246 + enzalutamide showed median rPFS 7.0 months; data at ASCO GU 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-108324","json":"https://secwatch.observer/filing/0001193125-26-108324.json","markdown":"https://secwatch.observer/filing/0001193125-26-108324.md","text":"https://secwatch.observer/filing/0001193125-26-108324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/0001193125-26-108324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:16:18.827373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}